CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities:
Income from continuing operations	$ 56,869	$ 45,217	$ 97,902
Income (loss) from discontinued operations, net of income tax (benefit) of ($46,851), ($59,881) and $325, respectively	(280,500)	(332,038)	901
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	45,887	50,775	4,667
Amortization and write-off of deferred loan costs	9,190	4,487	1,152
Amortization and write-off of debt discount	8,604	3,711	4,140
Share-based employee compensation expense	14,077	18,832	6,097
Loss on derivatives	14,544
Impairment of goodwill and intangible assets of discontinued operation	199,500	377,100
Loss (gain) on sale of business	90,163		(1,304)
Deferred income taxes	(38,438)	(52,076)	25,485
Decrease (increase) in accounts receivable, net	63,239	(8,283)	(12,311)
Decrease in other current assets	1,129	1,661	1,610
Decrease in accounts payable	(3,182)	(10,052)	(95)
Increase (decrease) in accrued salaries and benefits	128	3,608	(10,314)
Decrease in other current liabilities	(19,152)	(21,495)	(11,802)
Increase (decrease) in deferred revenue	686	(1,198)
Other	6,703	2,056	2,611
Net cash flows provided by operating activities	169,447	82,305	108,739
Cash flows from investing activities:
Acquisition of property and equipment	(15,525)	(24,713)	(9,053)
Proceeds from sale of business, net of cash transferred	558,067		1,416
Settlement on derivatives not designated as hedges	(1,499)
Business acquisitions, net of cash acquired		(1,062,818)
Net cash flows provided by (used in) investing activities	541,043	(1,087,531)	(7,637)
Cash flows from financing activities:
Proceeds from issuance of long-term debt	196,525	1,611,970	253,425
Payments of long-term debt	(795,100)	(574,329)	(373,536)
Proceeds from settlement of cash convertible notes hedges			141,246
Payments related to settlement of cash conversion derivative			(141,246)
Payments related to tax withholding for share-based compensation	(6,257)	(4,733)	(9,762)
Exercise of stock options	1,025	989	1,910
Deferred loan costs		(30,189)
Change in cash overdraft and other	(8,784)	2,083	410
Net cash flows provided by (used in) financing activities	(612,591)	1,005,791	(127,553)
Effect of exchange rate changes on cash		(12)	(56)
Net increase (decrease) in cash and cash equivalents	97,899	553	(26,507)
Cash and cash equivalents, beginning of period	2,486	1,933	28,440
Cash and cash equivalents, end of period	100,385	2,486	1,933
Supplemental disclosure of cash flow information:
Cash paid for interest	71,439	67,717	4,099
Cash paid for income taxes, net of refunds	20,433	$ 8,370	$ 3,339
Nutrisystem
Noncash investing activities:
Net working capital settlement expected from sale of Nutrisystem (see Note 2)	$ 2,844